Gefapixant Citrate single box market price analysis

Gefapixant Citrate (Gefapixant Citrate), as a new P2X3 receptor antagonist, is not currently on the market in China, so its domestic price and medical insurance reimbursement information are still uncertain. The situation in overseas markets can be used as a reference to help patients and clinicians understand the economic accessibility of drugs and investment in treatment.

Among the Japanese original drugs marketed overseas, the common specification of Gemfapixin is 45mg*100 tablets, with a price of about RMB 2,500 per box. Actual prices may vary due to factors such as exchange rate fluctuations and import taxes. As an original innovative drug, its price is relatively high, which mainly reflects drug research and development costs, clinical trial investment and marketing expenditures. This kind of price level usually needs to be reimbursed by medical insurance or commercial insurance in overseas markets to reduce the burden on patients.

At present, there are no generic drugs of Gemfapixane in China. The emergence of generic drugs usually requires the patent of the original drug to expire or obtain a production license. It is expected that as clinical trials and approval processes advance in the future, corresponding generic drugs may be launched in China, thereby reducing patient medication costs and improving accessibility. For clinicians, knowing overseas prices and drug specifications in advance can help plan long-term treatment strategies for patients, especially when continuous medication is required for the management of chronic cough.

Generally speaking, the price of a single box of Gemfapixin is relatively high overseas, but as an innovative drug for refractory chronic cough, it provides new treatment approaches and management strategies. The domestic launch time has not yet been determined, but with the advancement of drug registration review and market strategy, its price and medical insurance policy will gradually become clear in the future, providing more treatment options for patients with chronic cough.

Reference materials:https://synapse.patsnap.com